- Home
- SCNI vs DRMA Comparison
SCNI vs DRMA Comparison
Compare SCNI & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNI
- DRMA
- Stock Information
- Founded
- SCNI 2003
- DRMA 2014
- Country
- SCNI Israel
- DRMA United States
- Employees
- SCNI N/A
- DRMA N/A
- Industry
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- DRMA Biotechnology: Pharmaceutical Preparations
- Sector
- SCNI Health Care
- DRMA Health Care
- Exchange
- SCNI Nasdaq
- DRMA Nasdaq
- Market Cap
- SCNI 3.5M
- DRMA 1.9M
- IPO Year
- SCNI N/A
- DRMA 2021
- Fundamental
- Price
- SCNI $3.65
- DRMA $1.58
- Analyst Decision
- SCNI
- DRMA Strong Buy
- Analyst Count
- SCNI 0
- DRMA 1
- Target Price
- SCNI N/A
- DRMA $6.00
- AVG Volume (30 Days)
- SCNI 31.9K
- DRMA 188.1K
- Earning Date
- SCNI 10-29-2024
- DRMA 11-07-2024
- Dividend Yield
- SCNI N/A
- DRMA N/A
- EPS Growth
- SCNI N/A
- DRMA N/A
- EPS
- SCNI N/A
- DRMA N/A
- Revenue
- SCNI $284,000.00
- DRMA N/A
- Revenue This Year
- SCNI N/A
- DRMA N/A
- Revenue Next Year
- SCNI N/A
- DRMA N/A
- P/E Ratio
- SCNI N/A
- DRMA N/A
- Revenue Growth
- SCNI N/A
- DRMA N/A
- 52 Week Low
- SCNI $2.23
- DRMA $1.22
- 52 Week High
- SCNI $8.92
- DRMA $14.63
- Technical
- Relative Strength Index (RSI)
- SCNI 48.94
- DRMA 52.05
- Support Level
- SCNI $3.52
- DRMA $1.22
- Resistance Level
- SCNI $3.94
- DRMA $1.43
- Average True Range (ATR)
- SCNI 0.27
- DRMA 0.13
- MACD
- SCNI 0.00
- DRMA 0.02
- Stochastic Oscillator
- SCNI 52.31
- DRMA 76.60
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to develop and formulate singular and combination products that are able to target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases.